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ARTICLE
The parasitic worm product ES-62 normalises the
gut microbiota bone marrow axis in inﬂammatory
arthritis
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Aneesah M. Khan2, Paul A. Hoskisson 1, Margaret M. Harnett2 & William Harnett1
The human immune system has evolved in the context of our colonisation by bacteria,
viruses, fungi and parasitic helminths. Reﬂecting this, the rapid eradication of pathogens
appears to have resulted in reduced microbiome diversity and generation of chronically
activated immune systems, presaging the recent rise of allergic, autoimmune and metabolic
disorders. Certainly, gastrointestinal helminths can protect against gut and lung mucosa
inﬂammatory conditions by modulating the microbiome and suppressing the chronic
inﬂammation associated with dysbiosis. Here, we employ ES-62, an immunomodulator
secreted by tissue-dwelling Acanthocheilonema viteae to show that helminth-modulation of
the gut microbiome does not require live infection with gastrointestinal-based worms nor is
protection restricted to mucosal diseases. Speciﬁcally, subcutaneous administration of this
deﬁned immunomodulator affords protection against joint disease in collagen-induced
arthritis, a mouse model of rheumatoid arthritis, which is associated with normalisation of gut
microbiota and prevention of loss of intestinal barrier integrity.
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arasitic helminths (worms) have evolved to modulate host
immune and tissue repair responses to promote their
survival by limiting inﬂammation that would otherwise
drive their expulsion and cause pathology1. The recent eradica-
tion of helminths (and other pathogens) appears to have resulted
in over-activated immune systems and this provides a rationale
for the increasing prevalence of allergic and autoimmune
inﬂammatory disorders, as well as contributing to the rise in
obesity and associated comorbidities2–4 in developing and urba-
nised countries. Although genetic studies have identiﬁed gene
variants associated with various inﬂammatory diseases, these
alone do not appear to be strong risk factors, integration with
environmental factors being required to trigger disease. Recog-
nition of this has focused interest on the role of the microbiota3,5
and hence, on how helminths may regulate this in health
and disease6,7. Indeed, commensal bacteria and gastrointestinal
(GI) helminths appear to have evolved to reciprocally regulate
the gut microbiome8 to homeostatically maintain immune
system function2. Thus, GI helminths can induce regulatory
responses to limit inﬂammation and promote intestinal barrier
integrity, while intestinal bacteria play an essential role in training
the immune system by impacting on stem and progenitor cells3,5.
Certainly, there is increasing evidence from animal models
that protection afforded by GI helminth infection against
mucosal inﬂammatory disorders like asthma, inﬂammatory bowel
disease and coeliac disease, involves modulation of the gut
microbiota2,6,7.
Nevertheless, gut, lung or oral dysbiosis has also been impli-
cated in the aetiology of a wide range of autoimmune diseases,
including musculoskeletal pathologies like rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE)9,10. Whether
the protection afforded by GI helminths against these disorders
similarly involves interaction with the microbiome is not
clear but infection with Heligmosomoides polygyrus and Trichuris
muris can result in increases in Lactobacillaceae and decreases
in Prevotella species2,11,12, commensals reported to be dysregu-
lated in RA patients9,10. In any case, helminth-mediated protec-
tion against autoimmune disease is not limited to GI-tract
parasites, with particularly striking examples of this involving
ﬁlarial nematodes preventing development of RA13 and SLE14.
However, it is unclear whether tissue-resident or blood-borne
parasitic worms can mediate these effects via modulation of the
host microbiome and if so, which mechanisms they utilise.
That helminths can ameliorate chronic inﬂammatory
disorders has often been attributed to their capacity to excrete or
secrete molecules (ES) that exert immunoregulation2. Amongst
the best characterised ES products is ES-62, a phosphorylcholine
(PC)-containing glycoprotein secreted by the ﬁlarial nematode
Acanthocheilonema viteae that we have shown to prevent initia-
tion and progression of pathology in mouse models of certain
allergic (asthma, contact dermatitis) and autoimmune (RA, SLE)
inﬂammatory diseases1,2,15–20. Collectively, our studies have
identiﬁed a unifying mechanism of action that allows effective
protection irrespective of the inﬂammatory phenotype: thus, by
subverting TLR4 signalling to downregulate aberrant MyD88-
responses, ES-62 homeostatically resets the regulatory:effector
immune cell balance, primarily to restore levels of IL-10+
regulatory B cells and suppress pathological IL-17-driven
inﬂammation1,2,15–21. In both experimental models of RA and
human disease, perturbation of the microbiota has been shown
to disrupt the balance of pathogenic Th17 cells and the counter-
regulatory Bregs and Tregs that act to homeostatically resolve
inﬂammation9,10,22. Thus, our aim here was to investigate whe-
ther the anti-inﬂammatory actions of ES-62 reﬂected an ability
to impact on the microbiome. We now show that whilst joint
disease in the collagen-induced arthritis (CIA) mouse model
of RA is preceded by disturbance of the gut microbiome with
accompanying intestinal inﬂammation and loss of barrier integ-
rity, ES-62 acts to normalise the microbiome and maintain gut
health. Furthermore, we report that prophylactic depletion of the
gut microbiota with broad-spectrum antibiotics (ABX) reduces
the consequent severity of arthritis in mice undergoing CIA and
in addition, reduces the level of protection afforded by ES-62.
These data therefore indicate that a normalised microbiome is
required for the full induction of the immunoregulatory actions
of ES-62.
Results
ES-62 normalises the gut microbiome in protecting against
CIA. ES-62 ameliorates CIA in terms of articular score and
frailty, maintaining grip strength at a similar level to that of
healthy, Naive (not subjected to CIA) DBA/1 mice (Supplemen-
tary Figure 1). Commensal bacteria have increasingly been pro-
posed to contribute to RA pathogenesis9,10 and decline in grip
strength during ageing has been associated with changes in the
gut microbiome23. In addition to being an indicator of frailty, grip
strength is a predictor of a wide range of adverse health out-
comes24, e.g., cardiovascular disease, which RA patients are at
increased risk of developing25 and that are impacted by the
microbiome9,26. Thus, to address whether ES-62-mediated pro-
tection reﬂects modulation of the gut microbiota, a shotgun
metagenomic approach was used to proﬁle bacteria populations
present in the intestines of CIA mice. Initiation of RA (and CIA)
pathogenesis is associated with disruption of the balance of
effector:regulatory immune cells and so we characterised the
bacterial changes pertaining during established arthritis in the
ileum and colon; intestinal sites where the microbiome and
the metabolic microenvironment play key roles in shaping Th17
and regulatory immune responses22,27,28. As there is well-
documented variation in the microbiome amongst individuals
due to a range of environmental factors, we adopted the strategy
of pooling samples from mice with representative disease scores
to minimise variation due to a factor we could control for, namely
disease severity: speciﬁcally, we focused on those samples asso-
ciated with a well-established severe level of disease in CIA mice
(articular score: 7.00 ± 0.91) and clear protection against arthritis
in ES-62-treated CIA mice (articular score: 0.50 ± 0.33) over three
independent experiments.
An overview of the microbiota at the phylum level shows
substantial changes between healthy Naive mice and those with
arthritis (PBS; Fig. 1a). Firmicutes and Bacteroidetes are the
predominant phyla in all groups, but CIA mice in particular,
exhibit outgrowths of Firmicutes and Proteobacteria in the ileum,
whereas they demonstrate decreased levels of Firmicutes with a
compensatory outgrowth of Bacteroidetes, in the colon (Fig. 1a).
ES-62 essentially helps maintain the healthy microbiome diversity
of Naive mice, which was reduced in CIA mice (Fig. 1a). Deeper
analysis illustrates the differential diversity signatures of healthy
and arthritic mice, as well as the impact of ES-62 on a global
scale (Fig. 1b; Supplementary Table 1). As a consequence of our
pooling strategy, we have refrained from discussion of species-
level changes as large-scale population studies would be required
to address this with complete conﬁdence. Nevertheless, drilling
down on the modulation of the Gram-negative Bacteroidetes
phylum reveals differential signatures throughout each of the
predominant Bacteroides, Porphyromonas and Prevotella genera
and the Rikenellaceae family between the colon contents of Naive
and CIA mice, identifying those normalised by exposure to ES-62
(Fig. 1c). Similarly, in spite of the fact that differential proﬁles
amongst the groups were observed throughout major genera
(e.g., Bacillus, Staphyloccus, Streptococcus, Enterococcus and
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Clostridium) of Gram-positive Firmicutes (Fig. 1b; Supplemen-
tary Table 1), the most dramatic changes with established CIA
occurred within the Clostridiales order. In particular, decreases in
the Clostridiaceae and the Lachnospiraceae (Fig. 1d) families were
noted with ES-62 promoting maintenance of the Ruminococcus,
Faecalibacterium and Blauti genera and the family Erysipelo-
trichaceae in addition to the butyrate-producing genera Dorea
and Roseburia, the latter having been implicated in gut health and
inﬂammation homoeostasis29. In terms of the Proteobacteria,
CIA was associated with outgrowth of members of the
Helicobacter (Epsilonproteobacteria) and Escherichia (Gamma-
proteobacteria) genera and again this was normalised by ES-62
(Fig. 1e).
Perturbation of the microbiome was also observed in the ileum
of CIA mice and again, exposure to ES-62 normalised this
towards the healthy community (Fig. 1a). ES-62 clearly promoted
growth of the Clostridiales, again particularly the Clostridaceae
and Lachnospiraceae families, generally even beyond the levels
found in healthy mice (Fig. 1f ). In the context of the relative
paucity of bacteria in the ileum relative to the colon, this
outgrowth perhaps explains why ES-62 increases the overall
species diversity observed in the ileum but not the colon of CIA
mice (Supplementary Figure 2). In addition, reﬂecting that CIA
perturbs and ES-62 normalises gut bacteria, functional metage-
nomic analysis showed that ES-62 generally acted to normalise
the metabolic capacity of the colonic microbiome in CIA mice
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(Fig. 1g). Intriguingly, treatment of Naive, healthy mice with ES-
62 for the duration of the CIA model also promotes expansion of
members of the Clostridiales order, again particularly the
Lachnospiraceae, whilst decreasing abundance of Bacilli, the
Bacteroidaceae and Porphyromonadaceae families of Bacteroi-
detes and also, Proteobacteria in the ileum (Fig. 1h). Likewise, ES-
62 can also promote depletion of Bacteroidetes and expansion of
Ruminococcaceae and Clostridiaceae families and the Clostridia
class of Firmicutes in the colon of Naive mice (Fig. 1i).
Importantly, ES-62’s modulation of the gut microbiota in the
absence of the chronic inﬂammation associated with CIA suggests
that it can act directly, and that there is not an absolute
requirement for it to harness immunoregulatory mechanisms to
maintain and ﬁne-tune microbiome homoeostasis.
Antibiotics both ameliorate CIA and impact on ES-62 pro-
tection. To address whether microbiome perturbation observed
in CIA plays a role in the initiation and progression of inﬂam-
matory arthritis, we investigated the effect of continuous exposure
of mice to a cocktail of broad-spectrum antibiotics (ABX)
administered from 1 week prior to initiation of CIA. Such ABX
treatment had no obvious effect on overall health as, after a
characteristic initial dip, there was no signiﬁcant difference in
body weight amongst the CIA groups at cull (Supplementary
Figure 2). Nevertheless, this regimen essentially eliminated the
bacterial microbiota, irrespective of treatment group, whilst
metagenomic analysis showed the residual gut community to be
almost entirely comprising proteobacteria (Supplementary Fig-
ure 2). As predicted from previous studies in several inﬂamma-
tory arthritis models22,30,31, ABX treatment reduced the incidence
(PBS, 65.2%; PBS-ABX, 36.3%, as measured by articular score ≥1)
and severity of joint pathology in CIA mice, both in terms of
articular score (Fig. 2a) and histopathology (Fig. 2b, c). In addi-
tion, the protection afforded by ES-62 was reduced in ABX-
treated animals (Fig. 2a). Thus, prophylactic administration of
ABX resulted in an intermediate phenotype of CIA, irrespective
of whether the mice were treated with PBS or ES-62.
ES-62-mediated protection against CIA is associated with
restoration of the homoeostatic balance of regulatory:effector B-
cell responses via downregulation of aberrant MyD88 signalling2,21.
Typically, ES-62 reduces pathogenic anti-collagen type II (CII)
IgG2a, but not IgG1 antibody production32,33. Reﬂecting the ABX-
driven amelioration of CIA pathology, anti-CII Ig2a levels in PBS-
ABX mice are not signiﬁcantly different from those in ES-62-CIA
mice, whilst those in ES-62-ABX mice are not signiﬁcantly reduced
relative to those in PBS-CIA mice (Fig. 2d). No differences were
detected amongst any of the groups in terms of anti-CII IgG1
antibodies (Fig. 2e). Consistent with the effects of ABX on effector
B-cell responses, analysis of splenic IL-10+CD19+ Bregs showed
that both the decrease occurring during CIA (PBS-CIA) and also
the maintenance of healthy levels in ES-62-CIA mice2,21 were lost
in ABX-treated animals (Fig. 2f). Moreover, whilst ES-62 increases
serum IL-10 levels in CIA mice, this regulatory cytokine is found at
similarly low levels in PBS-CIA, PBS-ABX and ES-62-ABX mice
(Fig. 2g). At the same time, ES-62-mediated suppression of serum
levels of IL-6, a cytokine that promotes B-cell (auto)immunity34, is
lost following ABX treatment (Fig. 2h). Collectively, these ABX
studies indicate that depletion of the microbiota interferes with
generation of inﬂammatory mediators associated with CIA
pathogenesis as well as with the loss of immunoregulatory elements
(Bregs) normally contributing to resolution of chronic inﬂamma-
tion. Importantly, they also indicate that ES-62-resetting of the
effector:regulatory balance is dependent on an intact gut micro-
biome and hence suggest that its restoration is a consequence of ES-
62-mediated normalisation of the microbiome dysbiosis associated
with CIA.
ES-62 also acts in CIA mice to suppress the functional
maturation of osteoclasts (OC)20 that directly cause erosive joint
damage. Interestingly, changes in the intestinal microbiome have
been shown to impact on bone mass35,36 and we therefore
investigated whether the intermediate phenotype of joint
pathology occurring in ABX-treated CIA mice reﬂected modula-
tion of osteoclastogenesis resulting from perturbation of the gut
microbiota. Exposure of CIA mice to ES-62 restored the numbers
of OC differentiated from bone marrow (BM) progenitors ex vivo
to Naive levels (Fig. 3a) and blocked their fusion to large, active
multinucleated cells (Fig. 3a–c) that resorb bone20. Consistent
with its amelioration of CIA pathology, ABX administration
resulted in a decrease in large multinucleated OCs and a
corresponding increase in total numbers of BM-derived OCs
from CIA mice (Fig. 3a–c). Under these conditions of microbiota
depletion, the ability of ES-62 to inhibit generation of large
multinucleated OCs is lost (Fig. 3b): rather, and perhaps
consistent with the increased joint inﬂammation exhibited by
these mice, the ES-62-ABX group exhibits the largest multi-
nucleated cells of the ABX-treated cohorts, displaying signiﬁ-
cantly lower numbers of OCs but larger, multinucleated cells than
Naive-ABX mice. ES-62 rewires osteoclastogenesis by modulating
the RANK/OPG bone remodelling axis20 and this is evidenced
again here by its ability to signiﬁcantly decrease RANK
expression and increase (albeit not signiﬁcantly) expression of
the decoy receptor, OPG relative to that seen in BM of PBS-CIA
mice (Fig. 3d, e). This axis is also targeted by ABX treatment, with
the elevated RANK expression observed in PBS-CIA BM being
lost following ABX treatment. In addition, the elevated OPG
Fig. 1 ES-62 normalises the microbiome during CIA towards a Naive phenotype. The composition of bacterial phyla present in the ileum and colon of Naive,
PBS and ES-62-treated CIA animals, presenting proportion values as pie charts (a) from a single representative experiment using pooled samples from
three mice in each condition. b Heatmap analysis of all bacteria present in the colon of Naive, PBS and ES-62-treated CIA animals from this representative
model (articular scores; naive, 0; PBS-CIA, 6.3 ± 2.6; ES-62-CIA, 0; *p < 0.05 for PBS-CIA versus Naive and ES-62-CIA mice) is shown. The proﬁle of
bacterial abundance, is provided in Supplementary Table 1 for clarity. c–g Metagenonic analysis was performed on three independent models: in each
model, samples from three representative mice/group were pooled in each individual experiment and the mice selected exhibited the following articular
scores: Naive, 0; PBS-CIA, 7.00 ± 0.91; ES-62-CIA, 0.50 ± 0.33, where ***p < 0.001 for the PBS-CIA versus Naive and ES-62-CIA cohorts and n= 9 mice for
all groups over the three independent models. Statistically signiﬁcant changes (two-way ANOVA with LSD Fishers multiple comparisons) observed over
the three independent experiments (mean ± SEM, n= 3) between the PBS-CIA and ES-62-CIA groups in Bacteroidetes (c; Bacteroidaceae; PBS versus
Naive or ES-62, p < 0.05), Firmicutes (d; Clostridiales; PBS versus Naive, p < 0.01 and PBS versus ES-62, p < 0.05) and Proteobacteria (e;
Epsilonproteobacteria; PBS versus Naive or ES-62, p < 0.05) in the colon and Firmicutes in the ileum (f; Clostridiaceae; PBS versus ES-62, p < 0.05) as well
as functional metagenomics of the colon (g; Phages; Naive versus PBS, p < 0.01, Protein metabolism; PBS versus Naive or ES-62, p < 0.01) are presented as
heatmaps with changes in bacterial populations in PBS- and ES-62-treated CIA animals normalised to Naive controls. Ileum (h) and colon (i) faecal matter
from Naive or ES-62-treated Naive animals was analysed for changes in bacterial populations in a single experiment using samples pooled from three
animals per group and displayed as heatmaps, where the ES-62-treated samples are normalised to the Naive controls
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expression observed in ES-62-conditioned OCs was abrogated
following ABX treatment (Fig. 3d, e): these changes would result
in similar levels of RANKL-driven osteoclastogenesis consistent
with the intermediate CIA phenotype observed in PBS- and ES-
62-ABX animals. Supporting these ABX-changes in osteoclasto-
genesis and consequently bone damage, relative to Naive mice,
PBS-ABX and ES-62-ABX animals exhibit similar grip strengths
(70.8 ± 5.4% and 58.8 ± 6.0%, respectively) that are intermediate
to those displayed by PBS- (42.3 ± 6.2%) and ES-62-CIA mice
(90.1 ± 9.6%). Collectively, these data not only support a role for
the microbiome in osteoclastogenesis but also implicate its
involvement in the ability of ES-62 to modulate pathogenic
osteoclastogenesis in CIA.
ES-62 protects against gut pathology in CIA. Intestinal dys-
biosis has been associated with loss of gut integrity and chronic
inﬂammation in conditions such as obesity that promote auto-
immune disorders like RA and cardiovascular comorbidities37,38.
Our metagenomic analysis showed that established CIA
was associated with gut microbiome changes, in particular
with reduction in butyrate-producing bacteria (Fig. 1b, d;
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Fig. 2 Antibiotic treatment results in an intermediate disease phenotype. a Data are presented as articular scores (mean ± SEM) and are pooled from three
independent experiments (PBS; n= 23, ES-62; n= 19, PBS-ABX; n= 22 and ES-62-ABX; n= 22). b H&E staining (scale bars represent 200 µm) of hind
paws, from representative mice from each treatment group (clinical articular scores of individual paws were: PBS≥ 3 (n= 9), ES-62= 0 (n= 7), PBS-
ABX= 0 (n= 3) and ES-62-ABX≥ 3 (n= 3)) selected to compare joint pathology occurring in the similarly scored ES-62-CIA and PBS-ABX (score 0) and
ES-62-ABX and PBS-CIA (articular score≥ 3) mice. c Blind scoring of pathology exhibited in joint sections imaged in (b). d, e Levels of collagen II (CII)-
speciﬁc IgG2a (d; PBS; n= 18, ES-62; n= 13, PBS-ABX; n= 16 and ES-62-ABX; n= 14) and IgG1 (e; PBS; n= 15, ES-62; n= 10, PBS-ABX; n= 16 and ES-62-
ABX; n= 14) antibodies in serum were determined by ELISA. f Splenic B regulatory cells (CD19+IL-10+ cells) were determined by ﬂow cytometry (Naive;
n= 13, PBS; n= 21, ES-62; n= 14, Naive-ABX; n= 8 PBS-ABX; n= 14 and ES-62-ABX; n= 15). g, h IL-10 (g: PBS; n= 6, ES-62; n= 5, PBS-ABX; n= 6 and
ES-62-ABX; n= 6) and IL-6 (h: PBS; n= 24, ES-62; n= 10, PBS-ABX; n= 12 and ES-62-ABX; n= 13) concentrations in serum were determined by ELISA.
Statistics: all results are presented as mean ± SEM and each symbol represents an individual mouse; data are from one (g) or pooled from two or three
independent experiments. Statistical signiﬁcance was determined using two-way ANOVA (a) or one-way ANOVA (c–h) with LSD Fishers multiple
comparisons and signiﬁcance indicated by asterisks, *p < 0.05 and **p < 0.01 and #p < 0.05 (PBS vs. PBS+ABX [a] and ES-62-ABX vs. Naive [f])
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Supplementary Table 1) that have been implicated in main-
tenance of epithelial integrity and gut health29. Strikingly, mice
with CIA display severe gut pathology and inﬂammation, the
levels of which directly correlate with severity of CIA (Fig. 4a).
Moreover, ES-62 treatment protects against such gut damage,
speciﬁcally the thickening and generation of stubby villi in the
ileum (Fig. 4b, c) and hole-like lesions in the colon (Fig. 4b. d).
The physiological relevance of these colon lesions is unclear but
they may reﬂect the suppression of mucus production by goblet
cells in response to bacteria39 or alternatively, attachment/effa-
cement lesions induced by pathogenic bacteria, including
E. coli40. The gut pathology in PBS-CIA mice was diminished
in those administered ABX (Fig. 4b–d), suggesting that the
associated reduction in chronic gut (and consequently systemic)
inﬂammation contributes to the amelioration of CIA in PBS-ABX
mice. Of note, ES-62-ABX mice displayed increased pathology
and inﬂammatory cell inﬁltration of the gut tissue compared with
ES-62-CIA mice (Fig. 4b), ﬁndings again consistent with chronic
gut inﬂammation promoting disease severity.
To further address the role of gut pathology in CIA, we
analysed the ileum and colon tissue from Naive mice and those
undergoing CIA (treated with PBS or ES-62) at key points
during initiation and progression of disease: (i) Naive mice,
(ii) the breaking of tolerance and initiation of disease, following
immunisation with CII/CFA (≤ day 14), (iii) preclinical (day 21,
prior to booster immunisation with CII) and (iv) established
disease (≥ day 28; articular score: PBS–5.2 ± 0.8; ES-62–0.9 ±
1.24). This analysis revealed the presence of gut pathology in
PBS-CIA mice during the initiation phase with an increase in
both ileum villi thickness and colonic lesions following
immunisation (Fig. 5a–c). Interestingly, the ileum pathology
occurring during the initiation stage in PBS-CIA mice appeared
to resolve by the end of the preclinical phase (day 21), although
thickening and shortening of the villi was again induced by the
booster CII immunisation. This pattern was not the case for
the colon lesions, which peaked at day 21 and were maintained
throughout active disease in PBS-CIA mice. As opposed to CIA
mice, ileum integrity was maintained throughout all phases of
disease, whilst the high levels of colon lesions generated by day 21
of the preclinical phase were reduced in ES-62-treated animals
(Fig. 5b, c).
Supporting our metagenomics data, qPCR analysis showed that
ES-62 prevents the enrichment of Bacteroidetes and maintains
levels of Firmicutes in the colon of mice during established CIA
(Fig. 5d, e). However, analysis at the various phases of the disease
suggested a more dynamic situation: for example, following
the primary immunisation with CII/CFA, there is a signiﬁcant
decrease in levels of both Bacteroidetes and Firmicutes, with
the rise in Bacteroidetes evident in established arthritis only
occurring following the booster immunisation (Fig. 5d, e). By
contrast, ES-62 acts to maintain healthy levels of Firmicutes in
CIA mice throughout disease, but most strongly during the
initiation and preclinical phases and in addition, inhibits the
CIA-induced increase in Bacteroidetes during established disease.
Moreover, although ES-62 promoted enrichment of butyrate-
producing bacteria (Butyrivibrio) at all stages of disease, this was
most evident in the initiation phase (Fig. 5f). Butyrate has
been reported to promote the development of regulatory T cells
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(both Foxp3+ Tregs and IL-10+ Tr1 cells41,42) which by
suppressing and resolving chronic inﬂammation, could contri-
bute to the maintenance of gut barrier integrity. However,
whilst we ﬁnd that the induction of CIA is accompanied by loss
of splenic Tr1 cells, the predominant regulatory T-cell subset
defective in CIA43, ES-62 does not restore their levels back
towards those of Naive mice (Fig. 5g). These data are consistent
with our previous ﬁndings that protection against CIA afforded
by ES-62 is not associated with induction of either Treg or
Tr1 cell responses21. Moreover, ABX treatment does not
modulate either the CIA-associated depletion of Tr1 cells or the
failure of ES-62 to induce their restoration, suggesting their
development in this model is not impacted by the status of the
microbiome (Fig. 5g). Thus, collectively these data indicate
that ES-62 likely promotes Butyrivibrio species to maintain
butyrate-mediated protection of intestinal epithelium physiology
and barrier integrity44.
The dynamic changes observed in the gut during the initiation
phase further questions whether CIA-associated autoimmune
(Th17) inﬂammation is responsible for triggering gut pathology
and consequently, perturbation of the microbiome or vice
versa. Interestingly, therefore, whilst conﬁrming our ﬁndings
that dysbiosis and loss of intestinal barrier integrity are
established by day 14 in the CIA model, a very recent report45
shows that such breakdown in gut function precedes, and is
required for, CIA-associated IL-17 responses as increases in IL-17
can only be determined in the small intestine from day 14 whilst
those in the MLN occurred even later, being present during the
established disease phase (by day 35, but not detected on day 14),
and that ABX-depletion of the microbiota inhibits such IL-17
production and severity of joint disease. Moreover, these effects
appeared not to require (any) inﬂammation for initiation as they
could not be replicated by sham immunisation with CFA45.
Consistent with this idea that dysbiosis and associated gut
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pathology precedes and shapes the autoimmune inﬂammation
driving arthritis, we ﬁnd that CIA-associated perturbation of the
colon microbiota is evident as early as day 6 (post CII
immunisation): this is broadly normalised by exposure to ES-
62, with the worm product modulating levels of potentially
pathogenic bacteria (such as the Enterobacteriaceae family of
Gamma proteobacteria) to below those found in Naive animals
(Fig. 6a). Accompanying the CIA-dysbiosis, there is damage to
both the ileum and colon, with shortening and thickening of the
ileum villi particularly evident at this early time point and this is
protected against by ES-62 (Fig. 6b). These changes in gut
function occur in the absence of the systemic inﬂammation
(serum IL-6 cytokine and CII-speciﬁc IgG2a antibodies were only
present around the limit of detection of the ELISAs employed,
with no differences observed amongst Naive, PBS-CIA and ES-
62-CIA groups), known to be targeted by ES-62 in CIA (Fig. 2).
By contrast, the late microbiota-driven IL-17 responses developed
in the MLN in the clinical phase of CIA45 were suppressed by
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exposure to ES-62 (Fig. 6c). Collectively, these ﬁndings indicate
that ES-62 primarily acts directly to normalise the CIA-associated
gut dysbiosis that both triggers mucosal inﬂammation and
initiates the mesenteric lymph node (MLN) IL-17 responses
that drive autoimmunity, rather than indirectly modulating the
dysbiosis and gut pathology arising from the systemic inﬂamma-
tion that results from the CIA-immunisation protocol.
Although the precise details of how gut microbiome perturba-
tion occurs and drives chronic autoimmune inﬂammation and
joint destruction in CIA remain to be deﬁned, commensal
bacteria play key roles in educating the immune system and BM
progenitors and hence, loss of microbiome diversity can impact
on both inﬂammation and bone homoeostasis46,47. Such training
involves interactions of Pattern Recognition Receptors (PRR; e.g.,
TLRs and NODs) with the gut microbiome2,3,48. Consistent with
this, ES-62 can rewire BM progenitors and stromal cells from
CIA mice to an anti-inﬂammatory, regulatory or tissue repair
phenotype2,16,20,49–51 by subverting TLR4 signalling to prevent
the upregulation of the key TLR signal transducer, MyD88
observed during chronic inﬂammation52. Interestingly, therefore,
given the increased incidence and severity of CIA in ES-62-ABX
mice, we show that ES-62 dampening of aberrant MyD88
expression is abolished by ABX treatment (Fig. 6d).
Commensal bacteria can also dynamically educate OC
progenitor (OCP) maturation46,47: as OCs normally act in
concert with osteoblasts (OBs) to homeostatically maintain
healthy bone, the enhanced functional capacity of OCs elicited
by commensal bacteria may actually render hosts more
susceptible to bone damage during chronic inﬂammation, a
condition that promotes bone remodelling, particularly as
commensal bacteria also appear to act to suppress OB
function46,47. Reﬂecting the dynamic and differential changes in
the colonic microbiota, gut inﬂammation and pathology, there is
a strong increase in the monocyte populations containing OCPs
during the early inﬂammatory initiation phase of CIA that has
resolved by the end of the preclinical phase only to increase
again in the established phase of arthritis following the booster
CII immunisation. Consistent with our data that ES-62 does
not fundamentally suppress OC differentiation, there are no
differences in the percentage of monocytes between the PBS-CIA
and ES-62-CIA groups (Fig. 6e). However, following both
primary and booster immunisations, BM from CIA mice shows
enhanced capacity for functional OC maturation that is
suppressed by ES-62 (Fig. 6f, g).
Discussion
This study demonstrates that a deﬁned parasitic worm-derived
product can impact on, and harness, the microbiome to exert its
therapeutic effects against chronic inﬂammation in target organs
distal to the gut, such as the joints. Collectively, our data suggest
that ES-62-mediated protection reﬂects broad normalisation of
the gut dysbiosis observed in arthritic mice.
Potentially pathogenic changes in the gut microbiome have
been described following analysis of stool faeces from patients
with new-onset disease (enrichment of Prevotella copri10,53), as
well as those with established arthritis (changes in the Clos-
tridiaceae, Coriobacteriaceae and Lachnospiraceae families54,55).
Perhaps reﬂecting this, our metagenomic analysis of CIA mice
during the established disease phase shows ES-62’s protective
actions to be most strongly associated with maintenance of the
Clostridiaceae, Lachnospiraceae and Ruminococcaceae families,
particularly those associated with butyrate production, e.g.,
Ruminococcus. Administration of butyrate was previously found
to ameliorate CIA severity, notably in terms of reduction in each
of inﬂammatory cell inﬁltration of the joint, pannus formation
and cartilage and bone destruction56. By contrast, butyrate exa-
cerbated antibody-induced arthritis, a model which bypasses the
initiation and adaptive immunity phases of disease, suggesting
that butyrate needs to act during these preclinical phases to
exhibit its protective actions56. Possibly consistent with this,
whilst ES-62 protects against depletion of butyrate-producing
species in mice with established disease, we also ﬁnd Butyrivibrio
to be most enriched by ES-62 in the CIA initiation phase. Col-
lectively, these data suggest that depletion of butyrate-producing
bacteria associated with onset of CIA may contribute to the gut
pathology promoting and perpetuating the inﬂammation that
drives immune tolerance breakdown and consequent auto-
immune joint disease. Certainly, butyrate is known to regulate gut
barrier integrity44 and goblet cell production of MUC257. Indeed,
we ﬁnd microbiome dysbiosis and gut pathology to precede joint
disease onset, being observed within 6 days of primary CII
immunisation and in apparent absence of systemic inﬂammation.
Furthermore, the loss of colon barrier integrity peaks by the end
of the CIA preclinical phase (d21) and such gut pathology is
accompanied by dynamic changes in the microbiome of CIA
mice as evidenced by the decrease in colon abundance of Bac-
teroidetes and Firmicutes during the early initiation phase of
disease and the enrichment of the former during established
arthritis.
The normalisation of the gut microbiota by ES-62 may actually
result in a dual pronged mechanism by which butyrate, in
addition to its local gut-protecting actions, could also impact
systemically to protect more directly against joint pathology.
Consistent with this, butyrate has been reported to suppress
osteoclastogenesis58, and by protecting against pathological bone
loss, to regulate bone mass35. Intriguingly, we ﬁnd spikes of
functional maturation of OCs in the initiation and established
phases of CIA that are prevented by ES-62 and are associated
with its enrichment of Butyrivibrio. The mechanisms by which
Fig. 5 ES-62 protects against gut pathology occurring prior to onset of arthritis. a Representative H&E images (scale bars 200 µm) of ileum and colon of
mice culled during the Naive, initiation (post immunisation≤ d14), preclinical (d21 prior to challenge) and disease (established arthritis d≥ 28, articular
score PBS, 5.2 ± 0.8; ES-62–0.9 ± 1.24) phases of CIA. Changes in villus thickness (b; Initiation; PBS, n= 5, ES-62, n= 6, Pre-Clinical; PBS and ES-62, n= 3,
Disease; PBS, n= 4, ES-62, n= 5 mice) and number of colon lesions (c; Initiation; PBS and ES-62, n= 12 images spanning six mice each, Pre-Clinical; PBS,
n= 6 [3 mice], ES-62, n= 4 [2 mice]; Disease; PBS, n= 8 [4 mice], ES-62, n= 10 [5 mice]) were quantiﬁed using ImageJ analysis software with data
normalised to values of Naive mice and presented as mean ± SEM. Statistical signiﬁcance was determined using two-way ANOVA comparing PBS and
ES-62 treatment at each time point where **p < 0.01 and ***p < 0.001. d–f Changes in Bacteroidetes (d), Firmicutes (e) and Butyrivibrio (f) populations in
the colon faecal matter of Naive, PBS- and ES-62-treated animals were measured by qPCR, normalised to total bacterial content and presented as % Naive
mice. Data are presented as mean ± SEM values from individual animals (Initiation; n= 6, Pre-Clinical; n= 3, Disease; n= 10) and statistical signiﬁcance
determined using two-way ANOVA with LSD Fishers multiple comparisons where *p < 0.05, **p < 0.01 and ***p < 0.001. g Tr1 cells (CD3+IL-10+ cells)
were determined by ﬂow cytometric analysis of splenocytes from individual mice (Naive; n= 4, PBS; n= 7, ES-62; n= 4, Naive-ABX; n= 4 PBS-ABX; n= 6
and ES-62-ABX; n= 7) from a single experiment. Statistical signiﬁcance was determined using one-way ANOVA with LSD Fishers multiple comparisons
where *p < 0.05
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ES-62 orchestrates such maintenance of the complex homo-
eostasis of the gut-bone marrow axis are not clear. However, as
ES-62 can modulate the gut microbiota in Naive healthy mice, it
appears that such ﬁne-tuning of the microbiome can occur
directly, rather than indirectly via potential anti-inﬂammatory
and immunoregulatory actions that suppress gut pathology, to
protect against dysbiosis. It is therefore possible that ES-62 may
act in a manner analogous to quorum-sensing molecules59,60,
which are produced by bacteria and signal to regulate population
densities within a particular microbial niche. Thus, by coordi-
nating gene expression responses both within and across species,
quorum sensing molecules shape the microbial community and
its interaction with the host, particularly with respect to virulence
and pathogenesis;59,60 our future plans therefore encompass
determining whether ES-62 can modulate bacterial growth
directly as a starting point in investigating whether quorum-
sensing activities contribute to its ability to normalise microbiome
dysbiosis and maintain gut homoeostasis.
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However, in terms of CIA, our current working model is that
the induced dysbiosis may impact on MyD88-integrated micro-
biota-sensing intestinal epithelial-dendritic cell interactions61,62
to drive gut pathology and loss of barrier integrity and to train
inﬂammation and (auto)immune responses that in turn impact
on the microbiome and perpetuate chronic pathology. ES-62
exploits TLR4 to sense (aberrant) MyD88 signalling2 allowing
such changes in the microbiome to be detected by the helminth
product and enabling it to dynamically stabilise intestinal epi-
thelial barrier function and integrity and hence ﬁne-tune bacterial
species diversity and abundance to homeostatically maintain a
healthy microbiome. It is interesting therefore in this context that
systemic Th17 differentiation and consequent autoimmune
arthritis occurring in the IL1rn−/− model of RA is dependent on
TLR49,30. Moreover, the accompanying dysbiosis, that on faecal
transfer can confer arthritis-predisposing Th17 inﬂammation in
wild-type mice, is also regulated by TLR430. Furthermore, inter-
estingly, 11/44 taxa disrupted in IL1rn−/− mice were normalised
in IL1rn−/−TLR4−/− animals and these included Ruminococcus
species, which are also promoted by ES-6230.
In mechanistic terms, Breg levels—reset by ES-62 in CIA—
have also been reported to be regulated by the microbiome in
other models of autoimmune arthritis22. Indeed, consistent with
the proposal that Bregs are homeostatically induced to resolve
dysbiosis-induced inﬂammation in autoimmune arthritis, as
indicated by disruption of the process by ABX treatment22, we
have similarly found the ES-62-mediated restoration of IL-10+ B
cells, as well as the suppression of pathogenic anti-CII antibody
and IL-6 production, in CIA to be compromised by such per-
turbation of the microbiome. Collectively, these ﬁndings suggest
that by targeting MyD88 to maintain microbiome homoeostasis,
ES-62 may subsequently achieve its immunoregulatory effects,
which in turn, by dampening and resolving chronic inﬂamma-
tion, further contribute to the normalisation of intestinal barrier
integrity and the gut microbiome.
Given that normalisation of the gut microbiome appears cen-
tral to ES-62 resetting of immunoregulation in CIA, at ﬁrst sight
it may appear rather counter-intuitive that the worm product fails
to afford protection63 in mouse models of type-1 diabetes
(T1D), multiple sclerosis (MS) and inﬂammatory bowel disease
(IBD); conditions which have each been reported to exhibit
patterns of microbiome dysbiosis. However, it is likely that at
least in the dextran sodium sulphate (DSS) model of IBD that
the severe physical damage to the intestinal epithelial barrier
bypasses the capacity of ES-62 to normalise the microbiome,
as the resultant leakage and aberrant bacterial colonisation
would generate inﬂammation and pathology. In addition, loss
of regulatory T-cell function appears necessary for pathogenesis
in each of the T1D, MS and IBD models tested and ES-62 appears
to lack the capacity to restore either Treg or Tr1 responses in
all of the models of inﬂammatory diseases we have tested to
date2,63. This is perhaps rather surprising given the well-
documented induction of regulatory T cells by helminths2 and
the capacity of T2-MZP Bregs, to induce Tr1 and Tregs64.
However, we do not see signiﬁcant induction of T2-MZP
Bregs, but rather a general upregulation of IL-10+ B cells in the
CIA model21 where interestingly, we also fail to detect any
impact of the microbiome on Tr1 responses. Thus, one possibility
is that ES-62 only protects in models where (microbiota-
regulated) Bregs can directly mediate immunoregulatory effects,
such as CIA, MRL/Lpr-SLE and asthma models2. Consistent with
this, whilst roles for Bregs have been proposed in MS and IBD
(DSS) models, these appear to have been dependent on interac-
tions with regulatory T cells and indeed, the IBD-T cell transfer
models tested were performed in Rag1−/− mice that cannot
develop B cells63.
Finally, TLR4/MyD88 signalling in RA had previously been
attributed solely to recognition of DAMPs in the joint65 and
thus collectively, our ﬁndings shed new light on its pathogenic
roles in initiation and progression of disease as well as emphasise
its potential as a therapeutic target in RA. In particular, they
underscore the complex and central role of TLR4/MyD88 sig-
nalling in regulating the gut-bone marrow axis in musculoskeletal
homoeostasis and its dysregulation resulting in systemic inﬂam-
mation, breaking of tolerance, aberrant osteoclastogenesis and
consequently joint destruction in arthritis. Moreover, they suggest
that ES-62 may achieve its protective effects in CIA by directly
targeting this key regulatory node to normalise microbiome
dysbiosis and associated gut pathology in order to rebalance the
gut-bone marrow axis and limit aberrant inﬂammation and joint
damage, by consequently homeostatically restoring levels of Bregs
and resetting osteoclastogenesis. Thus, by exploiting ES-62 as a
unique tool to dissect pathogenic and protective microbial sig-
natures in CIA, we could potentially understand how to elicit
homoeostatic regulation of the gut and resolve inﬂammation in
autoimmune inﬂammatory arthritis.
Methods
Collagen-induced arthritis. Male DBA/1 mice were purchased at 6–8 weeks of age
(Envigo; Bicester, UK) and housed and maintained in the Central Research Facility
of the University of Glasgow. All experiments were approved by, and conducted in
accordance with, the Animal Welfare and Ethical Review Board of the University of
Glasgow, UK Home Ofﬁce Regulations and Licences PPL P8C60C865, PIL
I518666F7, PIL 1675F0C46 and PIL ICEBDB864.
CIA was induced using bovine Collagen Type II (CII: 100 μg) emulsiﬁed with
complete Freund’s adjuvant (MD Biosciences) injected intradermally on day 0.
Mice were challenged with 200 μg of CII in PBS intraperitoneally on day 21.
Animals were treated with PBS or puriﬁed endotoxin-free ES-62 (2 µg/injection)
subcutaneously on days −2, 0 and 21, and joint inﬂammation and damage
(articular score) were determined as described previously16,32,50. Grip strength was
recorded as per the manufacturer’s instruction (Ugo Basile®, Italy) using a
Gripometer, which measured the grip strength (peak force and time resistance) of
the forelimbs of the mice. The animals were placed over a base plate and gripped a
T-shaped grasping bar, which was connected to the peak ampliﬁer that
automatically detects the animal’s response. Three measurements were taken and
the average grip strength was calculated. In order to investigate the impact of gut
microbiome perturbation on initiation and progression of inﬂammatory arthritis,
animals were given drinking water containing [or not] a cocktail of antibiotics
(500 mg/L Vancomycin, 1 g/L Neomycin and 1 g/L Metronidazole) to eliminate
Gram-positive, Gram-negative and anaerobic microorganisms22 7 days prior to the
induction of CIA and thereafter continuously throughout the experiment. Blood
was sampled using endotoxin-free needles, and syringes and the resulting serum
isolated and stored at −20 °C in endotoxin-free Eppendorf tubes. Paw, ileum and
colon tissue was ﬁxed in 4% paraformaldehyde; ileum and colon faecal contents
were collected in sterile RNAlater (Sigma, UK) and stored at −80 °C. Endotoxin-
free ES-62 was puriﬁed from spent culture medium as described in detail
previously32.
Flow cytometry. Spleen, lymph node (LN) and bone marrow (BM) cells were
suspended in FACS buffer (2.5% BSA; 0.5 mM EDTA, in PBS) following red
blood cell lysis (eBioscience, UK). BM cells were labelled with a cocktail of PE-
labelled antibodies speciﬁc for CD3 (catalogue number: 100205), B220 (catalogue
number: 103207) and Ter119 (catalogue number: 116207) to exclude analysis
of lymphocytes and erythroid cell populations using a dump channel, and
monocytes were identiﬁed by labelling with antibodies against CD11b (FITC;
catalogue number: 101206), Ly6C (PerCP Cy5.5; catalogue number: 128011)
and Ly6G (APC; catalogue number: 127613)20. Lymphocytes were labelled with
antibodies speciﬁc for CD3 (FITC; catalogue number: 100305/6), CD19 (AF700;
catalogue number: 115527/8), IL-10 (PE or APC; catalogue number: 505007/9) and
IL-17 (PerCP5.5 or APC; catalogue number: 506915/6/9/20). For surface marker
staining, antibodies were used at 0.2 µg/106 cells (1/100 dilution) except for anti-
CD45, which was used at 1/200 dilution. For Fix/Perm staining of intracellular
cytokines, 1 µg/106 cells (1/20 dilution) were used. Gating strategies are shown
in Supplementary Figure 3. All antibodies were purchased from BioLegend, UK.
Fixable viability stain (APC-ef780; ThermoFisher Scientiﬁc, UK) was used to
select for live cells and for analysis of IL-10+ regulatory B cells (Bregs), lympho-
cytes were stimulated with PMA, ionomycin, Brefeldin A and LPS as described
previously18,21. Data were acquired using a FACS Canto or BD LSRII ﬂow cyt-
ometer and populations were gated as described previously using isotype and
ﬂuorescence minus one (FMO) controls using FlowJo, LLC analysis software
(Tree Star/BD)18,20,21,50,66.
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Histology. Ileum, colon and joint (paw) tissues from individual mice in each
treatment group were ﬁxed in 4% paraformaldehyde for 24 h before gut tissues
were embedded in OCT and paw joints were decalciﬁed and subsequently parafﬁn
embedded. Parafﬁn sections (6 μm) and OCT cryosections (9–10 μm) were pre-
pared and standard H&E histological staining was performed on all tissues for
identiﬁcation of morphological changes16,20,50. Ileum (villi thickness) and colon
(number of lesions) pathology was quantitated by ImageJ analysis. Joint pathology
was scored according to the grading system of 0 for no inﬂammation, 1 for mild
inﬂammation, pannus formation and bone damage, up to a score of 4 representing
a high level of inﬂammation, pannus inﬁltration and bone and cartilage destruc-
tion, as previously described67.
Osteoclast differentiation. OCs were differentiated from BM obtained from the
hind limbs of experimental animals as previously described20. Brieﬂy, following
removal of adherent cells, BM cells were cultured in αMEM medium supplemented
with 30 ng/ml M-CSF and 50 ng/ml RANKL (Peprotech, London, UK) and then
assessed for OC differentiation by TRAP staining (Leukocyte Acid Phosphatase Kit,
Sigma-Aldrich, UK) on day 5. Images were obtained using an EVOS FL Auto Cell
Imaging System. TRAP+ cells with ≥ 3 nuclei were enumerated, and ImageJ soft-
ware was used to calculate the average size of multinucleated OCs per ﬁeld of view
(FoV)20.
Serum cytokine and antibody ELISAs. Interleukin-6 (IL-6) and IL-10 expression
was measured by ELISA according to the manufacturer’s instructions (BD Bios-
ciences, Oxford, UK). For determination of collagen type II (CII)-speciﬁc IgG1 and
IgG2a antibodies in serum32, high-binding 96-well ELISA plates were coated with
CII (5 µg/ml) overnight at 4 °C before washing and blocking with BSA/PBS. Serum
was diluted 1:100 and then serially diluted threefold until 1:218,700 and incubated
with HRP-conjugated goat anti-mouse IgG1 or IgG2a (1:10,000) in 10% FBS/PBS
prior to developing with TMB and 2M sulphuric acid and read at an optical
density of 450 nm.
qRT-PCR. BM cells (106) were lysed in RLT lysis buffer prior to mRNA extraction
using RNeasy Plus Mini kit (Qiagen, Germany) according to the manufacturer’s
instructions. The High Capacity cDNA Reverse Transcriptase kit (Applied Bio-
systems, Life Technology, UK) was used to generate cDNA for use with StepOne
Plus™ real-time PCR system (Applied Biosystems, UK) and KiCqStart® qPCR
Ready Mix (Sigma-Aldrich). Pre-designed KiCqStart™ primers (Sigma-Aldrich)
were purchased to evaluate RANK (tnfrsf11a; forward: GAAATAAGGA
GTCCTCAGGG, reverse: GAAATAAGGAGTCCTCAGGG), OPG (tnfrsf11b;
forward: GAAGATCATCCAAGACATTGAC, reverse: TCCTCCATAAACTG
AGTAGC), MyD88 (myd88; forward: GAAGATCATCCAAGACATTGAC,
reverse: TCCTCCATAAACTGAGTAGC) and β-actin (actb; forward: GATGTAT
GAAGGCTTTGGTC, reverse: TGTGCACTTTTATTGGTCTC). Data were nor-
malised to the reference gene β-actin to obtain the ΔCT values that were used to
calculate the fold change from the ΔΔCT values following normalisation to bio-
logical control group.
Metagenomics. Given the well-documented variation amongst individual animals
that typically exhibit differential scores/affected joints in the CIA model and the
range of environmental parameters impacting on the microbiome68,69, we
attempted to minimise variation by pooling samples from three mice of similar
disease score/group from each independent CIA model rather than analysing each
individual mouse. Furthermore, pooling of samples also reduces variation in
sample and library preparation, whilst barcoding of these pooled samples allowed
analysis of the different treatment groups on a single chip and provided
internal controls for comparison of treatment groups within each experiment. This
process was repeated for three independent CIA models (involving nine repre-
sentative naive, PBS-CIA [articular score: 7.00 ± 0.91] and ES-62-CIA [articular
score: 0.50 ± 0.33, where ***p < 0.001 for the PBS-CIA versus naive and ES-62-CIA
cohorts] mice overall), further reducing the impact of disease score and individual
variation.
Genomic DNA from the ileum and colon faecal matter was puriﬁed using
QIAamp DNA Stool Mini Kit (Qiagen, Germany) and stored at −20 °C. For
shotgun metagenomic analysis using the Ion Torrent PGM™ platform, samples
from three individual mice per group were pooled and between 10 and 100 ng of
the pooled DNA was fragmented (NEB Fast DNA Fragmentation & Library Prep
Set for Ion Torrent, NEB Inc, UK) and barcoded (IonXpress Barcode Adapters Kit,
ThermoFisher Scientiﬁc, UK). Barcoded libraries were quantiﬁed using a Qubit
Fluorometer (ThermoFisher Scientiﬁc, UK) and bioanalyser (High Sensitivity DNA
analysis Kit, Agilent, UK). Up to three barcoded libraries were combined per Ion
316™ Chip Kit v2 following library preparation using the Ion PGM™ Hi-Q™ View
OT2 and Ion PGM™ Hi-Q™ View Sequencing Kits (ThermoFisher Scientiﬁc, UK).
Data were extracted as FASTQ ﬁles and analysed using MG-RAST to generate
taxonomic data from sequencing reads70. The number of reads per phylum, class,
order, family, genera or species of interest were expressed as a composition of all
bacteria present to normalise for variation between sequencing runs. Sequencing
runs can be accessed using MG-RAST IDs; mgm4777616.3, 4777615.3, 4777614.3,
4777613.3, 4777481.3, 4777480.3, 4777479.3, 4777478.3, 4767994.3, 4767993.3,
4767992.3, 4767991.3, 4767990.3, 4767989.3, 4767988.3, 4767987.3, 4767986.3,
4738191.3, 4738190.3, 4738025.3, 4737887.3, 4737053.3 and 4737052.3. qPCR
was used to validate changes in bacterial populations using primers speciﬁc for
Bacteroidetes (forward: GTTTAATTCGATGATACGCGAG, reverse: TTAAGCC
GACACCTCACGG)71, Firmicutes (forward: GGAGCATGTGGTTTAATTCGAA
GCA, reverse: AGCTGACGACAACCATGCAC)71, Butyrivibrio (forward:
GCGAAGAAGTATTTCGGTAT, reverse: CCAACACCTAGTATTCATC)72,
Proteobacteria (forward: TCGTCAGCTCGTGTCGTGA, reverse: CGTAAGGGC
CATGATG)73, Enterobacteriaceae (forward: GTGCCAGCAGC CGCGGTAA,
reverse: GCCTCAAGGGCACAACCTCCAAG)74, Lactobacillaceae (forward:
TGGAAACAGGTGCTAATACCG, reverse: GTCCATTGTGGAAGATTCCC)75,
segmented ﬁlamentous bacteria (forward: GACGCTGAGGCATGAGAGCAT,
reverse: GACGGCACGG ATTGTTATTCA)76, Lachnospiraceae (forward:
CGGTACCTGACTAAGAAGC, reverse: AGTTTCATTCTTGCGAACG)77 and
were normalised to the total levels of bacteria using pan-bacterial primers (forward:
CGGTGAATACGTTCCCGG, reverse: TACGGCTACCTTGTTACGACTT)77.
Statistics. All data were analysed using GraphPad Prism 6 software using one- or
two-way ANOVA with Fishers LSD post-tests for parametric data or
Kruskal–Wallis test and Dunn’s post test for non-parametric data. Unsupervised
hierarchical clustering with Euclidean distance was performed on the colon sam-
ples using the heatmap.2 function of the gplots package in R. Supervised heatmaps
were generated using GraphPad Prism 7 software. Indicators of signiﬁcance include
*p < 0.05, **p < 0.01 and ***p < 0.001.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data supporting the ﬁndings are all contained within the article and
Supplementary Information ﬁles. In addition, the metagenomic data are available from
the MG-RAST database using the accession numbers provided in the Methods section.
Other primary data ﬁles are available from the corresponding authors on reasonable
request.
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